Cover Image
市場調查報告書

動脈血栓症:開發中產品分析

Arterial Thrombosis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 293894
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
動脈血栓症:開發中產品分析 Arterial Thrombosis - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 61 Pages
簡介

動脈血栓症是動脈上產生了血塊,造成脈搏不整、肌肉酸痛、肌肉痙攣,皮膚蒼白,發冷等症狀。血塊發生的部位不同,會引發腦中風、心臟病發作、末稍動脈疾病(PAD)等各種不同的重症。吸煙及肥胖、糖尿病、高血壓、高膽固醇等是致病要素,治療法有血栓溶解藥及手術等。

本報告網羅全球動脈血栓症治療藥的開發平台資訊,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等資訊,為您概述為以下內容。

簡介

  • 調查範圍

動脈血栓症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

動脈血栓症:正在開發的治療藥:各企業

動脈血栓症:正在開發的治療藥:大學·研究機關別

動脈血栓症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

動脈血栓症:開發中的產品:各企業

動脈血栓症:開發中的產品:大學·研究機關別

動脈血栓症:治療藥的開發企業

  • Arena Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai
  • Johnson & Johnson
  • Sanofi

動脈血栓症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AS-1468240
  • ASP-1645
  • ASP-6537
  • BAY-1213790
  • BMS-593214
  • BMS-654457
  • C-3
  • E-5539
  • ER-410660
  • JNJ-375
  • 動脈血栓症·肺血栓性栓塞症的PAI-1阻礙胜肽
  • PZ-128
  • SAR-216471
  • temanogrel hydrochloride
  • ticagrelor
    • 產品概要
    • 作用機制
    • R&D的進展

動脈血栓症:最近的開發平台趨勢

動脈血栓症:暫停中的計劃

動脈血栓症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8444IDB

Summary

Global Markets Direct's, 'Arterial Thrombosis - Pipeline Review, H2 2016', provides an overview of the Arterial Thrombosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Arterial Thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Arterial Thrombosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Arterial Thrombosis
  • The report reviews pipeline therapeutics for Arterial Thrombosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Arterial Thrombosis therapeutics and enlists all their major and minor projects
  • The report assesses Arterial Thrombosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Arterial Thrombosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Arterial Thrombosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Arterial Thrombosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Arterial Thrombosis Overview
  • Therapeutics Development
    • Pipeline Products for Arterial Thrombosis - Overview
    • Pipeline Products for Arterial Thrombosis - Comparative Analysis
  • Arterial Thrombosis - Therapeutics under Development by Companies
  • Arterial Thrombosis - Therapeutics under Investigation by Universities/Institutes
  • Arterial Thrombosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Arterial Thrombosis - Products under Development by Companies
  • Arterial Thrombosis - Products under Investigation by Universities/Institutes
  • Arterial Thrombosis - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc.
    • AstraZeneca Plc
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eisai Co., Ltd.
    • Johnson & Johnson
    • Sanofi
    • Thromboserin Ltd
    • TSRL, Inc.
  • Arterial Thrombosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AS-1468240 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-6537 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAY-1213790 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-593214 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-654457 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-5539 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ER-410660 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FM-19 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-375 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PZ-128 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-216471 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • THL-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ticagrelor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Arterial Thrombosis - Dormant Projects
  • Arterial Thrombosis - Product Development Milestones
    • Featured News & Press Releases
      • Nov 13, 2014: AstraZeneca announces initiation of development programme for BRILINTA reversal agent
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Arterial Thrombosis, H2 2016
  • Number of Products under Development for Arterial Thrombosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Arterial Thrombosis - Pipeline by Astellas Pharma Inc., H2 2016
  • Arterial Thrombosis - Pipeline by AstraZeneca Plc, H2 2016
  • Arterial Thrombosis - Pipeline by Bayer AG, H2 2016
  • Arterial Thrombosis - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Arterial Thrombosis - Pipeline by Eisai Co., Ltd., H2 2016
  • Arterial Thrombosis - Pipeline by Johnson & Johnson, H2 2016
  • Arterial Thrombosis - Pipeline by Sanofi, H2 2016
  • Arterial Thrombosis - Pipeline by Thromboserin Ltd, H2 2016
  • Arterial Thrombosis - Pipeline by TSRL, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Arterial Thrombosis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Arterial Thrombosis, H2 2016
  • Number of Products under Development for Arterial Thrombosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top